Clinical trials for Primary myelofibrosis
46 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital · PI: Gabriela Hobbs, MD
- RECRUITINGPhase 3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd · PI: Xiao Zhijian, Doctor
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center · PI: Naveen Pemmaraju, MD
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura · PI: Michael Lahn, Dr
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine · PI: Angela Flesichman, MD, PhD
- ACTIVE NOT RECRUITINGNCT07342712Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsFirst Affiliated Hospital of Zhejiang University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06909136A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With MyelofibrosisSuzhou Junjing BioSciences Co., Ltd.
- RECRUITINGPhase 2NCT06770842Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisThe University of Hong Kong · PI: Harinder Gill, MD
- RECRUITINGPHASE1, PHASE2NCT06605586Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 InhibitionStichting Hemato-Oncologie voor Volwassenen Nederland · PI: Peter te Boekhorst, Dr.
- RECRUITINGPHASE1, PHASE2NCT06773195A Study of Ruxolitinib in Combination With Ulixertinib in People With MyelofibrosisMemorial Sloan Kettering Cancer Center · PI: Raajit Rampal, MD, PhD
- RECRUITINGNCT06533813Clinical Epidemiology in Contemporary Patients With Myelofibrosis.FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · PI: TIZIANO BARBUI, MD
- RECRUITINGPhase 1NCT06313593A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsIncyte Corporation · PI: Incyte Medical
- RECRUITINGPhase 3NCT06479135Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibKartos Therapeutics, Inc.
- RECRUITINGPhase 2NCT06457425A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd · PI: Zhijian Xiao, Doctor
- RECRUITINGPhase 2NCT05980806A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaKaryopharm Therapeutics Inc
- RECRUITINGPHASE1, PHASE2NCT06122831A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGNCT0616456118F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.First Affiliated Hospital of Zhejiang University · PI: Jie Sun, MD，Ph.D
- RECRUITINGN/ANCT07419178A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of ConceptAzienda Ospedaliero-Universitaria di Parma
- RECRUITINGPhase 1NCT05535764Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary MyelofibrosisUniversity of Utah · PI: Sagar Patel, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05393674Fedratinib in Combination With NivolumabInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · PI: Salah-Eddin Al-Batran, Prof. Dr.
- RECRUITINGPHASE1, PHASE2NCT05280509Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibTelios Pharma, Inc.
- RECRUITINGPhase 1NCT05371964A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisGeron Corporation · PI: Michelle Mudge-Riley, DO
- RECRUITINGPhase 2NCT05037760A Study of Elritercept Alone or Together With Ruxolitinib in Adults With MyelofibrosisTakeda · PI: Study Director
- ACTIVE NOT RECRUITINGPhase 2NCT05020652A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk MyelofibrosisChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ACTIVE NOT RECRUITINGPhase 2NCT04679870A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With MyelofibrosisGalecto Biotech AB · PI: Richard F Schlenk, MD
- ACTIVE NOT RECRUITINGPhase 3NCT04576156A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentGeron Corporation · PI: Faye Feller
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04817007A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Bristol-Myers Squibb · PI: Bristol-Myers Squibb
- ACTIVE NOT RECRUITINGPhase 2NCT04562870A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisKaryopharm Therapeutics Inc
- ACTIVE NOT RECRUITINGPhase 3NCT04562389Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisKaryopharm Therapeutics Inc
- RECRUITINGPhase 2NCT04370301Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary MyelofibrosisFred Hutchinson Cancer Center · PI: Rachel B. Salit
- ACTIVE NOT RECRUITINGPhase 2NCT04384692Peritransplant Ruxolitinib for Patients With Primary and Secondary MyelofibrosisFred Hutchinson Cancer Center · PI: Rachel B. Salit
- RECRUITINGPhase 2NCT04644016Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant DisordersMemorial Sloan Kettering Cancer Center · PI: Maria Cancio, MD
- ACTIVE NOT RECRUITINGPhase 1NCT04454658Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisAbbVie · PI: ABBVIE INC.
- ACTIVE NOT RECRUITINGPhase 3NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisAbbVie · PI: ABBVIE INC.
- ACTIVE NOT RECRUITINGNCT04217356Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk MyelofibrosisUniversity Health Network, Toronto · PI: Vikas Gupta, M.D.
- RECRUITINGPHASE1, PHASE2NCT04176198A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisSumitomo Pharma America, Inc.
- ACTIVE NOT RECRUITINGPhase 2NCT03645824Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)Stichting Hemato-Oncologie voor Volwassenen Nederland · PI: Peter AW te Boekhorst, M.D. PhD
- RECRUITINGPhase 3NCT03165734A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisSwedish Orphan Biovitrum · PI: Simran Singh
- ACTIVE NOT RECRUITINGPhase 1NCT03118492Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary MyelofibrosisCity of Hope Medical Center · PI: Monzr M Al Malki
- ACTIVE NOT RECRUITINGPhase 2NCT03069326A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With MyelofibrosisMemorial Sloan Kettering Cancer Center · PI: Raajit Rampal, MD, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT03333187Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor AvailabilityUniversitätsklinikum Hamburg-Eppendorf · PI: Nicolaus Kröger, Prof. Dr.
- RECRUITINGNCT02934477Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With MyelofibrosisCenter for International Blood and Marrow Transplant Research · PI: Wael Saber, MD
- RECRUITINGNCT02760238Myeloproliferative Neoplasms (MPNs) Patient RegistryUniversity Health Network, Toronto · PI: Vikas Gupta, MD
- ACTIVE NOT RECRUITINGPhase 4NCT02386800CINC424A2X01B Rollover ProtocolNovartis Pharmaceuticals · PI: Novartis Pharma, A.G
- RECRUITINGNCT01973881Quantitative MRI for MyelofibrosisUniversity of Michigan Rogel Cancer Center · PI: Gary Luker, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT00095784Decitabine in Treating Patients With MyelofibrosisNational Cancer Institute (NCI) · PI: Olatoyosi M Odenike